Finding a quality legal cannabis stock is not easy.
Out of the hundreds of cannabis-related stocks out there, I would venture to say that maybe about ten percent offer any real value for investors.
That’s not to say there isn’t plenty of potential out there. But potential must be approached carefully. After all, even the best ideas can be thwarted by unfortunate policy events, bad press or just shitty management.
That being said, whenever I can verify real potential, I dive right in. And that’s exactly what I did last year after getting the opportunity to take part in a private placement for Emblem Corp. (TSX-V:EMC).
Emblem Corp. is a licensed producer of cannabis in Canada that’s run by former Big Pharma execs. It’s the perfect combination of a superior form of medication and Big Pharma access and experience. Without a doubt, Emblem is a force.
In fact, we just got word this morning that Emblem has been able to successfully ramp up its patient acquisition program since launching back in November, when it only had 49 registered patients. Today, it has 2,091 active and pending patients. That’s an increase in excess of 4,000% in less than six months.
I remain bullish on Emblem and it continues to be one of our top picks for 2017.
Here’s a full list of the cannabis stocks we’re focused on right now, along with how they performed today …
- Aurora Cannabis (TSX-V: ACB) – Down 3.36%
- Aphria, Inc. (TSX-V: APH) – Down 2.8%
- Emblem Corp. (TSX-V: EMC) – Down 6.83%
- Emerald Health (TSX-V: EMH) – Down 5.79%
- Innovative Industrial Properties (NYSE: IIPR) – Up 2.7%
- OrganiGram (TSX-V: OGI) – Down 2.56%
- Canopy Growth Corporation (TSX: WEED) – Down 3%
Here’s what we’re buying …
Emerald Health (TSX-V: EMH) – Buying below $1.45
And here’s what we’re watching …
